Genmab Alternatives & Competitors
12 companies similar to Genmab — Differentiated human antibody therapeutics for the treatment of cancer
Companies similar to Genmab
Hemab Therapeutics
The next generation of therapeutics for bleeding and thrombotic disorders
Frederiksberg, Denmark
Immunocore
Science to Transform Lives
Abingdon, United Kingdom
Bolt Biotherapeutics, Inc.
Plans to develop a novel format for T-cell mediated anti-tumour therapy
Redwood City, United Stat...
Germany
Rival Readout
Competing with Genmab? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Calluna Pharma
Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis a...
Oslo, Norway
Arcus Biosciences
Biopharmaceutical company developing differentiated molecules and combination therapies fo...
Hayward, United States
Biomed Valley Discoveries
Biotech, Purposefully Reimagined
Kansas City, United State...
ImmunGene
Innovation in antibody-cytokine fusion technology and monoclonal antibody-based therapies...
Novelogics Biotechnology Inc.
Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer us...
Canada
DEM Biopharma, Inc.
Novel Target for Solid Tumors
Cambridge, United States
Pyxis Oncology
Charting a course to therapeutics for difficult-to-treat cancer.
Boston, United States
FatiAbGen Inc.
Best in class multi-modality antibodies for difficult targets in high unmet need diseases...
Korea South
About Genmab
Genmab, founded in 1999, is a pioneering international biotechnology company headquartered in Denmark. Renowned for its expertise in antibody innovation, Genmab focuses on developing differentiated human antibody therapeutics aimed at treating cancer and other serious diseases. Through its innovative approach, the comp...
Development of Antibody Therapeutics, Pipeline of Medicines, Biotech Research
Healthcare Professionals, Patients & Care Partners, Investors, Corporate Partners
Antibody Therapeutics, Cancer Treatment, Bispecific Antibodies, Antibody-Drug Conjugates, Immune-Modulating Antibodies, Clinical Pipeline, Innovative Medicines, Antibody Innovation, Late-stage Clinical Trials, Biopharmaceuticals, Healthcare Innovation, Unmet Medical Needs, Drug Development
B2B, B2C, B2D
Licensing, Product Sales, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Genmab: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Genmab on 25 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
